12,372 trials
Episodic Cluster Headache
Primary: Overall Mean Change From Baseline in Number of Weekly Cluster Headache Attacks — -5.22; -8.69 Cluster Headache Attacks per Week — p=0.036
Atrial Fibrillation
Primary: Percentage of Participants With Composite Endpoint of Stroke, Systemic Embolic Stroke (SEE), Myocardial Infarction (MI) and Cardiovascular (CV) Mortality From…
Primary Care
Primary: Consultation and Relational Empathy (CARE) Measure — 44.69; 41.99 units on a scale — p=0.029
Spasticity
Primary: Number of Subjects With Adverse Events — 129; 150; 44 Count of participants
Bronchoscopy
Primary: Number of Participants With a Successful Procedure — 250; 3; 24 Participants — p=<0.0001
Prostate Cancer
Primary: Time to Progression — 683.0; 549.0 days — p=0.76
Ulcerative Colitis · Crohn's Disease
Primary: Percentage of Participants With One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 93; 96; 31; 41 percentage of participants
Colorectal Carcinoma
Primary: Overall Survival — 4.44; 4.76 Months — p=0.337
Lennox-Gastaut Syndrome
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Rufinamide — 54; 38; 9; 2 Participants
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.95; -0.65 Percentage of HbA1c — p=<0.0001
Basal Cell Carcinoma (BCC)
Primary: Overall Patient Complete Response Rate Assessed 12 Weeks After the Last PDT — 93.4; 91.8 Percentage of Patients — p=<0.0001
Nicotine Dependence
Primary: Number of Participants With Cotinine-confirmed 7-day Point Prevalence Abstinence at the End of Treatment — 4; 4 Participants
Spinal Puncture
Primary: Duration of Apnea — 110; 73 seconds
Anesthesia
Primary: Number of Participants With Body Movement During Anesthetic Maintenance — 165; 111; 54; 50 participants
Urothelial Carcinoma
Primary: Progression Free Survival (PFS) — 4.07; 2.76 Months — p=0.0118